生命科学资讯
生物技术与制药领域的最新动态
Round three of IRA negotiations is expected to be ‘manageable’ for pharma
口服落健制造商Veradermics拟通过IPO融资1.81亿美元
Oral Rogaine maker Veradermics looks to raise $181M from IPO
FDA请求法院暂停路易斯安那州堕胎药争议。
FDA asks court to pause Louisiana's abortion pill fight
龙沙集团仍计划出售其胶囊与健康配料业务
Lonza still intends to sell its capsules and health ingredients business
龙沙集团仍计划出售其胶囊与健康成分业务——Endpoints新闻
Lonza still intends to sell its capsules and health ingredients business - Endpoints News
梯瓦制药CEO宣布公司已成功转型为生物制药企业。
Teva CEO says it has successfully transitioned into a biopharma company
FDA暂停再生元基因疗法试验，因患者出现脑瘤。
FDA suspends Regenxbio gene therapy trials after patient developed brain tumor
美国卫生与公众服务部拟在特朗普医保计划启动前，为制药商规避反回扣法提供保护。
HHS seeks to protect drugmakers from anti-kickback laws ahead of TrumpRx launch
Eikon计划通过IPO融资2.73亿美元，其研发管线以中国抗癌药物为主导。
Eikon seeks $273M IPO with pipeline led by Chinese cancer drugs
Included Health推出替代性健康计划
Included Health launches alternative health plan
恒瑞医药引领潮流，中国药企志在全球市场。
Hengrui blazes trail as Chinese drugmakers aspire to go multinational
勃林格殷格翰推进罕见肾病药物进入三期试验，尽管中期数据令人困惑。
Boehringer Ingelheim takes rare kidney disease drug to Phase 3 despite puzzling mid-stage data
CMS选定礼来Trulicity和吉利德Biktarvy进入第三轮Medicare价格谈判。
CMS picks Lilly’s Trulicity, Gilead's Biktarvy for third round of Medicare negotiations
美国医保服务中心提议：医院采购美国制造药品可获得更多收益。
Hospitals could earn more for buying US-made drugs, CMS proposes
卡迪夫高管离职，公司二期试验数据喜忧参半。
Cardiff execs depart as company drops mixed Phase 2 data
联合健康集团调整业务布局，预计2026年营收将下滑
UnitedHealth projects lower revenue in 2026 as it resets its business
FDA解除对Intellia两项三期基因编辑研究之一的暂停。
FDA lifts hold on one of two Phase 3 gene editing studies by Intellia
英矽智能与齐鲁制药达成1.2亿美元心血管代谢疾病药物研发合作
Insilico’s latest deal is a $120M cardiometabolic drug discovery pact with Qilu Pharma
阿斯利康终止心血管药物研发；Lisata与齐鲁制药终止合作协议。
AstraZeneca ends work on cardio drug; Lisata and Qilu terminate deal